Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

High Proteolytic Resistance of Spider-Derived Inhibitor Cystine Knots.

Kikuchi K, Sugiura M, Kimura T.

Int J Pept. 2015;2015:537508. doi: 10.1155/2015/537508.

2.

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.

Reh L, Magnus C, Schanz M, Weber J, Uhr T, Rusert P, Trkola A.

PLoS Pathog. 2015 Jul 9;11(7):e1004966. doi: 10.1371/journal.ppat.1004966.

3.

HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Acharya P, Lusvarghi S, Bewley CA, Kwong PD.

Expert Opin Ther Targets. 2015 Jun;19(6):765-83. doi: 10.1517/14728222.2015.1010513. Review.

4.

Thermosensitive and mucoadhesive pluronic-hydroxypropylmethylcellulose hydrogel containing the mini-CD4 M48U1 is a promising efficient barrier against HIV diffusion through macaque cervicovaginal mucus.

Bouchemal K, Aka-Any-Grah A, Dereuddre-Bosquet N, Martin L, Lievin-Le-Moal V, Le Grand R, Nicolas V, Gibellini D, Lembo D, Poüs C, Koffi A, Ponchel G.

Antimicrob Agents Chemother. 2015 Apr;59(4):2215-22. doi: 10.1128/AAC.03503-14.

5.

Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops.

Moscoso CG, Xing L, Hui J, Hu J, Kalkhoran MB, Yenigun OM, Sun Y, Paavolainen L, Martin L, Vahlne A, Zambonelli C, Barnett SW, Srivastava IK, Cheng RH.

Sci Rep. 2014 Nov 14;4:7025. doi: 10.1038/srep07025.

6.

Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site.

Kwon YD, LaLonde JM, Yang Y, Elban MA, Sugawara A, Courter JR, Jones DM, Smith AB 3rd, Debnath AK, Kwong PD.

PLoS One. 2014 Jan 28;9(1):e85940. doi: 10.1371/journal.pone.0085940.

7.

Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.

Roitburd-Berman A, Dela G, Kaplan G, Lewis GK, Gershoni JM.

Retrovirology. 2013 Dec 5;10:147. doi: 10.1186/1742-4690-10-147.

8.

Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.

Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS.

J Virol. 2014 Jan;88(2):1125-39. doi: 10.1128/JVI.02566-13.

9.

Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1.

Glotzbach B, Reinwarth M, Weber N, Fabritz S, Tomaszowski M, Fittler H, Christmann A, Avrutina O, Kolmar H.

PLoS One. 2013 Oct 11;8(10):e76956. doi: 10.1371/journal.pone.0076956.

10.

Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein.

Morellato-Castillo L, Acharya P, Combes O, Michiels J, Descours A, Ramos OH, Yang Y, Vanham G, Ariën KK, Kwong PD, Martin L, Kessler P.

J Med Chem. 2013 Jun 27;56(12):5033-47. doi: 10.1021/jm4002988.

11.

Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1.

Acharya P, Luongo TS, Louder MK, McKee K, Yang Y, Kwon YD, Mascola JR, Kessler P, Martin L, Kwong PD.

Structure. 2013 Jun 4;21(6):1018-29. doi: 10.1016/j.str.2013.04.015.

12.

Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Mann A, Friedrich N, Krarup A, Weber J, Stiegeler E, Dreier B, Pugach P, Robbiani M, Riedel T, Moehle K, Robinson JA, Rusert P, Plückthun A, Trkola A.

J Virol. 2013 May;87(10):5868-81. doi: 10.1128/JVI.00152-13.

13.

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

De Feo CJ, Weiss CD.

Viruses. 2012 Dec;4(12):3859-911. Review.

14.

MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques.

Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P, Bouchemal K, Ponchel G, Ramos OH, Herrera C, Stefanidou M, Shattock R, Heyndrickx L, Vanham G, Kessler P, Le Grand R, Martin L.

PLoS Pathog. 2012;8(12):e1003071. doi: 10.1371/journal.ppat.1003071.

15.

Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.

Moseri A, Tantry S, Ding FX, Naider F, Anglister J.

AIDS Res Hum Retroviruses. 2013 Apr;29(4):718-24. doi: 10.1089/AID.2012.0189.

16.

Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120.

Shrivastava IH, Wendel K, LaLonde JM.

Biochemistry. 2012 Oct 2;51(39):7783-93. doi: 10.1021/bi300878d.

17.

MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.

Grupping K, Selhorst P, Michiels J, Vereecken K, Heyndrickx L, Kessler P, Vanham G, Martin L, Ariën KK.

Retrovirology. 2012 May 2;9:36. doi: 10.1186/1742-4690-9-36.

18.

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.

Abela IA, Berlinger L, Schanz M, Reynell L, Günthard HF, Rusert P, Trkola A.

PLoS Pathog. 2012;8(4):e1002634. doi: 10.1371/journal.ppat.1002634.

19.

Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides.

Kassler K, Meier J, Eichler J, Sticht H.

Adv Bioinformatics. 2011;2011:736593. doi: 10.1155/2011/736593.

20.

Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, Lian Y, Geonnotti AR, Montefiori D, Franti M, Martin G, Carfi A, Kessler P, Martin L, Srivastava IK, Barnett SW.

PLoS One. 2012;7(1):e30233. doi: 10.1371/journal.pone.0030233.

Items per page

Supplemental Content

Support Center